Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 11, 2021

SELL
$3.36 - $10.56 $135,102 - $424,607
-40,209 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$9.26 - $14.36 $175,940 - $272,840
-19,000 Reduced 32.09%
40,209 $396,000
Q4 2020

Feb 12, 2021

SELL
$9.84 - $14.26 $106,183 - $153,879
-10,791 Reduced 15.42%
59,209 $642,000
Q3 2020

Nov 12, 2020

BUY
$10.3 - $21.64 $206,000 - $432,800
20,000 Added 40.0%
70,000 $721,000
Q2 2020

Aug 12, 2020

SELL
$8.53 - $25.64 $117,287 - $352,550
-13,750 Reduced 21.57%
50,000 $1.04 Million
Q1 2020

May 14, 2020

BUY
$7.98 - $16.32 $508,725 - $1.04 Million
63,750 New
63,750 $623,000

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $783M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Chi Advisors LLC Portfolio

Follow Chi Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chi Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chi Advisors LLC with notifications on news.